SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection

Brief summary

This is a Phase I/II gene therapy trial treating X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector (ivlv-X1) to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the direct intravenous lentiviral gene transfer protocol.

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

status

NOT_YET_RECRUITING

phase

PHASE1, PHASE2

study type

INTERVENTIONAL

enrollment

10

sponsor

Shenzhen Geno-Immune Medical Institute

conditions

SCID, X-Linked

interventions

BIOLOGICAL: Direct intravenous injection of ivlv-X1 lentiviral vector

start date

2027-06-30

start date type

ESTIMATED

primary completion date

2028-12-31

has results

false

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters